Impact of the US Preventive Services Task Force Grade D Recommendation: Assessment of Evaluations for Elevated Prostate-specific Antigen and Prostate Biopsies in a Large Urology Group Practice Following Statement Revision

Kathleen F McGinley; Gregory C McMahon; Gordon A Brown

Impact of the US Preventive Services Task Force Grade D Recommendation: Assessment of Evaluations for Elevated Prostate-specific Antigen and Prostate Biopsies in a Large Urology Group Practice Following Statement Revision

Rev Urol. 2015;17(3):171-7.

Authors

Kathleen F McGinley, Gregory C McMahon¹, Gordon A Brown

Affiliation

¹ Department of Urology, Rowan University School of Osteopathic Medicine, Stratford, NJ.

PMID: 26543432
PMCID: PMC4633661

Abstract

On October 7, 2011, the United States Preventive Services Task Force (USPSTF) released their evidence statement and grade D recommendation against prostate-specific antigen (PSA)-based prostate cancer screening. Using a time series design, we assessed the effect of this recommendation upon evaluations for elevated PSA levels and prostate biopsies in our large urology group practice. We found that, despite a 24.1% increase in total visits, the 32 urologists in our practice completed 16.4% fewer evaluations for elevated PSA levels (317 fewer evaluations per month; P = .017) and 21.4% fewer prostate biopsies (42 fewer biopsies per month; P = .001) in the 2 years following the USPSTF grade D recommendation.

Keywords: Prostate biopsies; Prostate cancer screening; Prostate-specific antigen; United States.